The ATP5IF1 Knockout HeLa Polyclonal Cells product comprises a heterogeneous population of CRISPR/Cas9-edited HeLa cells with targeted disruption of the ATP5IF1 gene. This polyclonal knockout cell pool enables functional studies of ATP5IF1 in cancer metabolism without the limitations of clonal selection. Through CRISPR/Cas9-mediated gene disruption, these cells provide a loss-of-function model to investigate the endogenous inhibitor of mitochondrial ATP synthase and its role in metabolic adaptation.
The host cell line, HeLa, is a widely used HPV18-positive cervical adenocarcinoma cell line exhibiting deficiencies in the tumor suppressors p53 and Rb. These immortalized cells serve as a robust model for cervical cancer research, characterized by rapid proliferation and a transformed metabolic phenotype that recapitulates key aspects of tumor metabolism, including high glycolytic flux and altered mitochondrial dynamics.
ATP5IF1 functions as an endogenous inhibitor of the F1Fo-ATP synthase, specifically blocking its hydrolytic activity under conditions of hypoxia to prevent cellular ATP depletion. This protein interacts directly with ATP synthase subunits such as ATP5A1 and ATP5B, as well as with Hsp70, cyclophilin D, and the adenine nucleotide translocator (ANT). ATP5IF1 is regulated upstream by mTORC1, HIF1A, AMPK, and PGC-1??, and its inhibition of ATP synthase preserves mitochondrial membrane potential and attenuates cytochrome c release, thereby linking metabolic state to apoptosis and mitochondrial dynamics. Through these interactions, ATP5IF1 promotes a glycolytic metabolic phenotype, integrating signals from nutrient-sensing pathways such as mTOR and hypoxia-driven transcriptional programs.
In the HeLa cellular context, ATP5IF1 knockout is expected to enhance ATP synthase activity, shifting metabolism toward oxidative phosphorylation and altering cristae morphology. Given that HeLa cells are inherently glycolytic due to HPV oncogene expression and p53/Rb loss, loss of ATP5IF1 disrupts the balance between glycolysis and oxidative phosphorylation, potentially sensitizing these cells to metabolic stress or drugs targeting mitochondrial function. This model is thus highly relevant for dissecting the mechanisms of cancer metabolic reprogramming, hypoxia adaptation, and mitochondrial dysfunction in tumor cells.
Researchers can employ these polyclonal knockout cells in a variety of assays to assess metabolic remodeling, including Seahorse metabolic flux analysis, ATP synthase activity measurements, Western blotting for key metabolic enzymes, RT-qPCR for metabolic gene expression, mitochondrial membrane potential assays, and immunofluorescence to visualize mitochondrial morphology. The model supports investigations into cancer metabolism, hypoxia response, mitochondrial dynamics, drug resistance, and apoptosis. For detailed inquiries, please contact Ascent Research.
